Alan Levey, MD, PhD, Director of Emory’s Alzheimer’s Disease Research Center, commented on the findings making news: “We were amazed to see the accumulation of LSD1 in neurofibrillary tangles in Alzheimer’s, and in TDP-43 aggregates in FTD” (Published in Nature Communications this week)
Incisive article from the NIA on challenges and new strategies for patient recruitment into AD clinical trials.
In this article we explore recruitment issues, including those unique to Alzheimer’s studies, and we suggest concrete steps such as establishing a structured consortium linking all of the registries of Alzheimer’s trials and establishing new partnerships with community and local organizations that can build trust and understanding among patients, caregivers, and providers.
In the largest-ever genetic analysis conducted on Alzheimer’s disease, an international group of researchers has identified 11 new genes associated with the disorder, doubling the number of known gene variants linked to it.
The International Genomic Alzheimer’s Project, a collaboration of two groups in the United States and two in Europe, scanned the DNA of 74,076 older volunteers from 15 countries — including people with and without the disease — to look for subtle gene variants involved in late-onset Alzheimer’s, the most common form.
Held in the historic Austrian capital, the 13th AD/PD conference reflected a rapidly growing field. The meeting jammed science into five parallel sessions, with 545 talks running from early morning till late evening and some 1,200 posters vying for attention.
Led by Mt Sinai Alzheimer’s researcher and thought leader Mary Sano, PhD, and coordinated by the ADCS, the HBA study compared feasibility and efficiency, and ability to capture change over time using in-home instruments, and ability to predict cognitive conversion using pre-defined triggers in a randomized clinical trial.
View the best moments of the 13th International Conference on Alzheimer’s & Parkinson’s Diseases. Mechanisms, Clinical Strategies, and Promising Treatments of Neurodegenerative Diseases
From WashPo for the layman, why we should be excited by the lymphatic system developments.
Concerns over the Zika virus have focused on pregnant women due to mounting evidence that is causes brain abnormalities in developing fetuses. However, new research in mice suggests that certain adult brain cells may be vulnerable to infection as well.
Today the Senate Committee on Appropriations approved a bill that would boost U.S. government funding for Alzheimer’s disease to almost $1.4 billion in fiscal year 2017.
Exercise may help to keep the brain active in people with an increased risk of developing Alzheimer’s disease, according to a new study conducted by the Cleveland Clinic.
The findings suggest that even moderate amounts of physical activity may help to slow the progression of Alzheimer’s.
Exciting news in the hunt for novel AD-related biomarkers: Learn more about the “memory protein” – NPTX2
Memory loss in Alzheimer’s disease (AD) is attributed to pervasive weakening and loss of synapses. Here, we present findings supporting a special role for excitatory synapses connecting pyramidal neurons of the hippocampus and cortex with fast-spiking parvalbumin (PV) interneurons that control network excitability and rhythmicity.
Stanford researchers identify iron-containing microglia in the brains of people with Alzheimer’s disease
Examining post-mortem tissue from the brains of people with Alzheimer’s disease, Stanford University School of Medicine investigators identified what appear to be iron-containing microglia in a particular part of the hippocampus, a key brain structure whose integrity is critical to memory formation.
Dr. Neil Buckholtz of the NIA discusses ADNI in a summary of the recent presentations at the AAIC in Copenhagen and other Alzheimer’s research news.
From early morning to late evening, at symposium and plenary sessions, during poster sessions and coffee breaks, at add-on meetings and consortium sessions, some 4,300 investigators from 75 different countries shared recent findings and explored ways to overcome the challenges of finding ways to treat or prevent this complex disease.
Researchers presenting at the Alzheimer’s Association International Conference 2016 (AAIC 2016) in Toronto introduced and described a new condition or patient status, known as Mild Behavioral Impairment (MBI), that may be a forerunner of neurodegeneration and progression to mild cognitive impairment (MCI) or dementia.
Disclosing Amyloid Status in an Alzheimer’s Prevention Trials – First A4 Study Disclosure Results Published in JAMA Neurology
From the accompanying JAMA Neurology editorial “What is clear is that, with the advance of molecular diagnostic tools in neurology, clinicians and investigators will increasingly be faced with the challenge of presenting patients with information of uncertain prognostic significance. The investigators of the A4 study are to be commended for developing a thoughtful process of…
Can exercise slow or prevent cognitive decline in older people at increased risk for Alzheimer’s disease?
The new NIA-supported EXERT study, in partnership with the YMCA, is looking to find the right dose of exercise to slow memory loss.
Biohaven and Alzheimer’s Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate AD.
The Biohaven Pharmaceutical Holding Company Ltd. announced today its clinical trial collaboration with the Alzheimer’s Disease Cooperative Study (ADCS).
Axovant’s interpirdine fails to meet the trial’s primary endpoints. Read the Alzheimer’s Forum interpirdine report
What potential therapy reports out next? There are not a lot of large, late stage, Alzheimer’s trial results expected until 2019 (including Biogen’s aducanumab, Merck’s BACE- oriented verubecestat, and Lilly/AstraZeneca’s lanabecestat).
Are humans the only ones who are able to remember events that they had experienced and mentally time travel not only into the past but also the future? Or do animals have the same capacity?
The model developed by the three researchers Prof Markus Werning, Prof Sen Cheng and Prof Thomas Suddendorf differs from other approaches with regard to one major aspect: it suggests a new relationship between mental time travel and episodic memory.